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Abstract
Interleukin-2  receptor  antagonists  (IL-2RA)  are  frequently  used  as  induction  therapy  in  liver 
transplant  recipients  to  decrease  the  risk  of  acute  rejection  while  allowing  the  reduction  of 
concomitant  immunosuppression.  The  exact  association  with  the  use  of  IL-2RA  however  is 
uncertain. We performed a systematic literature search for relevant studies. Random effects models 
were used to assess the incidence of acute rejection, steroid-resistant rejection, graft loss, patient 
death,  and  adverse  drug  reaction,  with  or  without  IL-2RA.  Six  studies  (2  randomized  and  4 
nonrandomized) met the elegibility criteria. Acute rejection at 6 months or later favored the use of 
IL-2RA significantly (relative risk (RR) 0.38; 95% confidence interval (CI) 0.22-0.66, p = 0.0005). 
Although not statistically significant, IL-2RA showed a substantial reduction of the risk of steroid-
resistant  rejection (RR 0.32;  CI 0.19-1.03,  p = 0.0594).  Graft  loss  and patient  death showed a 
reductive tendency through the use of IL-2RA. The use of IL-2RA is safe and is associated with a 
statistically  significantly  lower incidence of  acute  rejection  after  transplantation  and substantial 
reduction of steroid-resistant rejection, graft loss and patient death.
Key  words:  liver  transplantation,  immunosuppression,  interleukin-2  receptor  antagonist,  meta 
analysis, pediatric, basiliximab, daclizumab, controlled study
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Introduction
The ultimate purpose of pediatric liver transplantation is to grant an expectance of life of several 
decades. Immunosuppression should be tailored to ensure best management of both short and long 
term complications. Currently the immunosppressive strategey is not standardized among different 
transplantation  centers  mainly  because  very  few comparative  studies  with  adequate  number  of 
patients and duration of follow-up are published (1-3). In particular, only a few published controlled 
clinical studies report on the use of a relatively new immunosuppressive agent called basiliximab 
(Simulect®) or daclizumab (Zenapax®). These are monoclonal antibodies targeting the interleukin-
2  (IL-2)  receptor  (IL-2R).  Initially  they  were  approved  for  therapy  of  patients  after  renal 
transplantation.  The  two  IL-2R  antibodies  (IL-2RA)  daclizumab  and  basiliximab  were 
commercially  available,  but  daclizumab  has  recently  been  withdrawn  from  the  market  for 
commercial  reasons.  Now  basiliximab  is  regulary  used  in  adult  as  well  as  in  pediatric  liver 
transplant both in Europe (4) and in the US (5). 
The aim of induction therapy with IL-2RA is mainly to decrease the risk of acute rejection. Acute 
rejection should be prevented because a graft is damaged with each rejection and loses part of its  
function. There are histopathologic features of acute and chronic rejection proved by core needle 
biopsy (6). Avoiding acute rejection (AR) or steroid-resistant (acute) rejection (SRAR) is improves 
the long time function of a liver graft. For children a good functioning and long living liver graft is 
particularly important due to the high expected lifespan. Acute rejection is a strong risk factor for 
chronic rejection in kidney transplant patients (7). Acute rejection after liver transplantation can 
progress  to  chronic  injury, it  shows  a  prolonged  liver  dysfunction,  and  all  lead  on  to  chronic 
rejection (6). It could be a similar strong risk factor for liver recipients, but the development is not 
well understood by now (8). Chronic rejection is also described as a potentially reversible process 
with a dynamic nature (8). There is no evidence based connection between acute rejection and long-
term outcome in liver transplantation. FDA regulated clinical research focuses on acute rejection as 
primary endpoint, leading to less information about long-term data and other endpoints. The idea of 
using IL-2RA is  an exchange of immunosuppressive drugs  without  increasing the risk of  graft 
damage to reduce long lasting effects of common immunosuppressive substances such as steroids 
and  calcineurin  inhibitor  (CNI).  Common  side  effects  of  steroids  include  infections,  arterial 
hypertension, glucose intolerance, hyperlipidemia and osteoporosis (9). There are some side effects 
which differ  from adult  liver  graft  recipients.  Children  suffer  from growth impairment  (9)  and 
steroids may influence hepatic regeneration and development of immunologic tolerance (10). The 
use of CNI bears the risk of developing renal dysfunction after liver transplantation because of its 
nephrotoxicity (1-3). 
IL-2RA specifically  bind and block the IL-2R α-chain (which corresponds to  CD25),  which is 
present only on the surface of activated T-lymphocytes (11). The IL-2 signal is essential for the 
activation of lymphocytes; it induces second messenger signals to stimulate T cells to enter the cell 
cycle and proliferate, resulting in clonal expansion and differentiation. The commercially available 
IL-2RA are both monoclonal anti-CD25 immunoglobulin G (IgG) antibodies, but their structure and 
synthesis are different. Daclizumab is a humanized antibody built by total  gene synthesis using 
oligonucleotides  (12),  whereas  basiliximab  is  a  chimeric  murine-human  antibody  (13).  The 
competitive  block of  IL-2R,  and thereby of  IL-2-mediated  activation,  lasts  for  4  to  12  weeks, 
depending on the antibody and the administration protocol (11). The following side effects have 
commonly  been  observed  in  conjunction  with  the  use  of  IL-2RA:  CMV  or  EBV  infection  / 
reactivation, lymphoproliferative disorders, anaphylaxis, fever, opportunist infection, hypotension / 
hypertension,  digestive  disturbances,  hyperglycemia,  hirsutism,  pruritus  and  antibody  formation 
(14). 
In the present study, we conduct an analysis of published controlled trials examining the effect of 
IL-2RA in children after liver transplantation. We would like to investigate whether the use of IL-
2
2RA in addition to concomitant immunosuppressive therapy reduces acute rejection and steroid-
resistent  rejection after pediatric liver  transplantation.  We expect that  the potential  reduction of 
concomitant medication such as CNI or steroids through the additional therapy with IL-2RA will 
reduce the long-term adverse drug reaction (ADR) such as kidney failure, disturbance of growth, 
diabetes mellitus and other metabolic disorders.
Material and methods
The  methods  of  literature  search,  the  inclusion  and  exclusion  criteria,  outcome  measures  and 
methods of statistical analysis were established according to the recommendations in the Cochrane 
Handbook for Systematic Reviews of Interventions (15, Part 2). We also used the Preferred Items 
for Systematic Reviews and Meta-Analysis (PRISMA) (16) to structure this report. The methods of 
this meta-analysis were similar to those used in (17).
Literature search
A systematic literature search was performed without language restrictions in December 2012 in the 
following  databases:  PubMed,  Transplant  Library  and  Cochrane  Library.  The  following  search 
terms  were  used:  “liver  transplantation,“  “interleukin  2  receptor  inhibitor/antagonist,“ 
“basiliximab,“  “daclizumab,“  “zenapax,“  “simulect,“  “pediatric,“  “child,“  “children,“  and 
abbreviations thereof. The keywords were combined with Boolean operators.
Inclusion and exclusion criteria
All prospective,  controlled pediatric studies and pediatric  studies with prospective experimental 
group and historical control group in which IL-2RA induction therapy in liver transplant recipients 
was  compared  with  placebo  or  no  add-on  were  included.  A first  nonsystematic  review of  the 
literature showed that in pediatric liver transplantation IL-2RA are used in addition to standard 
immunosuppression therapy concepts to reduce other immunosuppressive drugs, such as CNI (3) 
and  corticosteroids  (9-10).  We have  therefore  structured  this  meta-analysis  into  three  separate 
comparisons  as  follows:  In  the  first  group  IL-2RA is  added  to  the  experimental  group and is 
compared  to  no  add-on  or  placebo,  while  both  study  arms  got  equal  concomitant 
immunosuppressive medication. This group is referred to as the  IL-2RA only comparison in the 
following.  In  the  second  group  IL-2RA  is  additionally  combined  with  delayed  CNI  in  the 
experimental arm (delayed CNI comparison). The third group compared IL-2RA with a standard 
immunosuppressive protocol with reduced or even dropped steroids in the experimental arm (the 
no/low steroids comparison).  Other  immunsuppressive  medication  had  to  be  the  same  in  both 
treatment arms, e.g., mycophenolate mofetil (MMF).
All  retrospective,  noncontrolled  pediatric  studies  and  pediatric  studies  with  multiorgan 
transplantation or retransplantation were excluded. Pharmacological studies that did not provide 
data on clinical outcome measures were excluded as well because of their very short follow-up 
time. The literature search strategy was designed and performed by two reviewers (N.D.C., A.D.G.). 
Publications were screened independently by two reviewers (N.D.C., A.D.G.). Disagreement and 
any discrepancies were resolved by discussion of all four reviewers.
Outcome measures
The  primary  outcomes  analysed  were  acute  rejection,  steroid-resistant  rejection,  graft  loss  and 
patient death.  Secondary outcomes were ADR namely renal  dysfunction by need of dialysis  or 
oliguria, de novo malignancy (excluding recurrence of hepatocellular carcinoma), post transplant 
lymphoproliferative disease (PTLD), infection complications, including fungal, viral and bacterial 
infections,  new  onset  of  metabolic  and  cardiovascular  disorders  such  as  arterial  hypertension 
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(HTN), hyperlipoproteinemia (HLP) and posttransplant diabetes mellitus (PTDM).
Study quality
The quality items assessed were blinding, randomization, allocation concealment, intention-to-treat 
(ITT) analysis, completeness of follow-up, and the method of handling missing values. Assessment 
was performed according to definitions stated in the Cochrane Handbook (15, Ch. 8). Quality of 
studies was assessed independently by two reviewers (N.D.C., A.D.G.) without blinding to journal 
and authorship. Furthermore, completeness of follow-up was defined as the number of patients that 
were  not  lost  to  follow-up.  We reported  completeness  of  follow-up  as  stated  by  the  authors. 
Methods of handling missing values are stated as reported by the authors of the respective study.
Data extraction
All available data for the described outcome measures were extracted at all available timepoints 
from individual trials. In contrast to kidney transplants, it has been shown that morphological signs 
of  rejection  in  protocol  biopsies  of  transplanted  livers  without  clinical  correlates  require  no 
treatment and have no long-term ADR (18). Therefore, we only included treated acute rejections in 
the  primary  analysis,  when  the  reported  acute  rejection  was  stratified  into  ‘‘treated’’  and 
‘‘nontreated.’’ When  data  on  outcome  measures  were  not  provided  or  studies  seemed  to  be 
duplicates, the authors were contacted to provide more data. Data extraction was performed by one 
reviewer (N.D.C.) using a standardized form and checked by two reviewers (A.D.G, C.R.).
Data analysis
We expressed  the  results  of  dichotomous  outcomes  as  relative  risk with  values  smaller  than  1 
favoring  IL-2RA.  When  no  event  was  observed  in  both  arms,  we  excluded  it  from  the 
corresponding  comparison  (15,  Ch.16.9.3).  We performed  the  analysis  using  a  random effects 
model, as in case of doubt it makes more sense to use the more general approach (including the 
fixed-effects model as a special case), which will usually lead to more conservative results (19). For 
the random effects  models  the amount  of residual  heterogeneity (i.e.,  τ²)  was estimated by the 
restricted maximum likelihood (REML) method (20). Confidence intervals for τ² were obtained by 
the Q-profile method (21). The model parameters were estimated by way of weighted least squares, 
with weights equal to the inverse sum of the variance of the estimate and the estimate of the residual 
heterogeneity.  Then  Wald-type  tests  and  confidence  intervals  were  obtained  for  the  parameter 
estimates (20). We analyzed heterogeneity among studies using Cochrane’s Q test and calculating I² 
to measure the proportion of total variation due to heterogeneity beyond chance (22). We performed 
subgroup  analyses  for  primary  outcomes  which  had  significant  results.  Subgroups  and  factors 
defined  a  priori  were  methodological  quality  of  trial  (i.e.,  randomized  versus  nonrandomized), 
comparison group, type of IL-2RA, type of CNI, and use of mycophenolate mofetil (MMF). For the 
primary  analysis  we pooled effect  measurements  from trials  with  different  follow-up time;  but 
timepoint of measurement (grouped by 6 months versus 12 months and later) was evaluated in a 
subgroup analysis. In some of the subgroups a valid analysis was not possible. In order to examine 
the influence of covariates affecting the direction and/or strength of the relation between dependent 
and  independent  variables  we  used  the  moderator  test.  For  statistically  significant  results  we 
calculated the number needed to treat (NNT) describing how many patients are needed to be treated 
with an intervention, here IL-2RA, to prevent one patient from having one additional bad outcome, 
here for example acute rejection. Publication bias was assessed using funnel plots (23) and tests for 
funnel  plot  asymmetry  (20).  The R environment  for  statistical  computing  (v. 2.11.0)  (24)  with 
packages “meta“ (v. 2.5-0) (25), ‘‘metafor’’ (v. 1.4-0) (20), and ‘‘lme4’’ (v. 0.999375-37) (26) were 
used for all analyses.
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Results
Literature search
Database searches yielded 325 entries (see Fig.1), of which 15 were excluded as duplicates. Of the 
remaining 310 publications that qualified for abstract review, 252 were excluded primarily because 
they were not controlled trials, the effect of IL-2RA was not investigated, they were not dealing 
with pediatric patients or they were not conducted in patients undergoing first liver transplantation. 
Also retrospective studies  were excluded.  The remaining 58 publications  underwent  full  article 
review  and  38  further  publications  were  excluded.  Most  common  reasons  were  retrospective 
studies,  other  comparator  than  IL-2RA,  studies  with  adult  patients,  non  controlled  studies  and 
reviews. A total of 20 trials qualified for inclusion in this review. 13 studies were excluded because 
of being duplicates, preliminary reports and follow-up reports of the included studies. One study 
was excluded because of having no reported follow-up time and the authors did not respond to our 
requests of further information. Six studies were eventually included for analysis (1-3, 9-10, 27). All 
trials were obtained as full-text puplications. In case of multiple reports on the same study we cited 
the most recent full-text publication as the index publication. Two authors of reports were contacted 
in order to resolve ambiguities. One author answered, the other author did not respond.
Included studies
Table 1 shows the characteristics of the included studies. Three trials (1-2, 27) compared IL-2RA to 
no treatment  without  modification of concomitant  immunosuppressive medication (IL-2RA only 
comparison). Only one trial (3) compared IL-2RA in combination with delayed CNI to no treatment 
with standard immunosuppression (delayed CNI comparison). Two trials (9-10) compared IL-2RA 
in combination with early discontinuation or reduction of steroids to no treatment with standard 
immunosuppression (no/low steroids comparison). One study (9) excluded patients with a severe 
renal dysfunction and another trial (10) excluded children with autoimmune hepatitis. In two-thirds 
of the included studies basiliximab was used for induction (1, 9-10, 27) and another two-thirds of 
the trials used tacrolimus as CNI (2-3, 9-10). Two of the six studies used MMF (2-3) and all but the 
experimental arms of the studies of no/low steroids comparison (9-10) used steroids as concomitant 
medication. Most trials had a study duration of 12 months or more (3, 9-10, 27).
Quality of included studies
Table 2 shows the quality assessment of the included studies. None of the studies were classified as 
blinded,  whereas two of them did not report  the status of blinding and were classified as „not 
stated“.  Two  studies  (3,  9)  were  prospective  and  randomized,  a  third  study  (2)  was  entirely 
prospective and three studies (1, 10, 27) had a prospective experimental group and historical control 
group. Of the randomized trials, allocation concealment was found to be adequate in none of the 
studies, but unclear in one study (9) and inadequate (3) in another. For the four nonrandomized 
studies  (1-2,  10,  27)  allocation  concealment  was  not  applicable.  ITT  analysis  was  stated  and 
performed in one study (9) and was assessed as adequate. In three further trials (2, 10, 27) ITT 
analysis was assumed and considered adequate because the authors reported on all patients at the 
endpoints of the study. One study (1) reported ITT analysis  but it  was assessed as inadequate. 
According to the definition given in (15, Ch. 16.2.1), the authors of that trial did a per-protocol (PP) 
analysis. In only one trial (3) we could not assess ITT analysis and it was therefore classified as  
„not stated“. None of the authors stated how missing values were handled. Only two studies (9-10) 
described completeness of follow-up. 
Application of IL-2RA
Table 3 summarizes the immunosuppressive therapy of included pediatric trials. Basiliximab was 
used in four studies (1, 9-10, 27). All of them administered basiliximab on postoperative day-0 and 
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4 in a dosage of 10mg for children with a weight below 30 kg or a dosage of 20mg for children with 
a  weight  of  more  than  30  kg.  In  addition  Spada  et  al.  2006  (9)  administered  basiliximab  on 
postoperative days-8 until -10 if the recipient had lost more than 70 ml/kg fluid from the abdominal 
drains, because basiliximab crosses into the ascitis fluid (3). Daclizumab was used as induction 
therapy adapted to patient's weight (1mg/kg) in two trials (2-3) and was therefore administered on 
postoperative day-0. Schuller et al. 2005 (2) in addition gave a second dose on postoperative day-
14. In the immunosuppressive concepts of the studies discussed here, the authors tried to limit the 
overall immunosuppression (3). Daclizumab has a half-life of 99hr and it's loss in ascitic fluid has  
been only weakly correlated to the monoclonal antibody clearance (3, p 2040). Heffron et al. 2003 
(3) used it in the first week after transplantation instead of CNI, whereas Schuller et al. 2005 (2)  
used daclizumab induction to reduce the target level of tacrolimus from the beginning.
Definition of primary outcomes
Most studies defined acute rejection as a rejection episode (1-2, 9-10), confirmed by liver biopsy (1, 
3, 9-10, 27), and for which therapy was given (2-3, 9-10, 27). Some trials described a clinical and 
laboratory diagnosis in addition (3, 27). The severity of AR was graded by using the Banff criteria  
(28) in two studies (9, 27). A steroid-resistant acute rejection was defined as not past by using  
steroids (2-3, 9, 27) and therefore a treatment with for example OKT3 (3, 9) was needed. Some 
studies proved it by biopsy (3, 27). Spada et al. 2006 (9) also used CNI in standard dose first before 
adding steroids. 
Follow-up time of included studies
Follow-up  times  varied  from  6  up  to  52  months.  They  also  differed  between  control  and 
experimental group and were not necessarily identical for all outcomes. Because of the different 
follow-up times a comparison is difficult, but the first 6 months are the crucial period in which IL-
2RA is acting. The long time effects on outcome of patients should be measured over years. We 
have not found enough data on long-term outcomes. Most follow-up is about 3 years only.
Primary ouctomes
Acute rejection. Reduction of acute rejection favored the use of IL-2RA (RR 0.38; CI 0.22–0.66; p 
= 0.0005; 6 trials; Fig. 2). The effect is also seen in the subgroup of randomized trials (RR: 0.31; CI 
0.20–0.47; p < 0.0001; 3 trials), but is not statistically significant in nonrandomized studies (RR: 
0.46; CI 0.18–1.18; p = 0.1039; 3 trials). The relative risk (RR) of all studies had a statistically 
significant heterogeneity (p=0.0126) which is due to the study of Gibelli et al. 2004 (1). Omitting 
the study by Gibelli et al. 2004 (1) the risk reduction is larger (RR 0.30; CI 0.21–0.43; p < 0.0001; 5 
trials). Considering the three pre-specified subgroups of studies, we have data on the IL-2RA only 
comparison (RR: 0.44; CI 0.19–1.002; p = 0.0507; 3 trials) and on the no/low steroids comparison 
(RR: 0.31; CI 0.12–0.84; p = 0.0211; 2 trials). Only the no/low steroids comparison was significant 
in reduction of acute rejection, favoring the use of IL-2RA. Stratifying studies by follow-up time 
showed a statistically significant reduction of acute rejections with IL-2RA at 12 months and later 
(RR 0.31; CI 0.21–0.45; p < 0.0001; 4 trials), but not at 6 months (RR 0.51; CI 0.16–1.66; p = 
0.2654; 2 trials). Furthermore, subgroup analysis stratified by the type of IL-2RA used showed a 
statistically significant effect of both basiliximab (RR 0.44; CI 0.21–0.92; p = 0.0299; 4 trials) and 
daclizumab (RR 0.29; CI 0.18–0.47; p < 0.0001; 2 trials). The subgroup with daclizumab induction 
therapy got additional MMF as immunosuppressive concomitant medication,  it  showed a lower 
p-value and showed no statistically significant heterogeneity. Stratifying trials by type of CNI used 
showed a statistically significant effect of tacrolimus (RR 0.30; CI 0.19–0.46; p < 0.0001; 4 trials)  
but not for cyclosporine A (RR 0.53; CI 0.20–1.40; p = 0.1999; 2 trials). Finally we analysed the 
subgroup  stratified  by  control  group.  Studies  with  retrospective  control  group  showed  no 
statistically significant reduction of acute rejection (RR 0.46; CI 0.18–1.18; p = 0.1039; 3 trials) in  
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comparison to these with prospective control group (RR 0.31; CI 0.20–0.47; p < 0.0001; 3 trials). 
The number needed to treat (NNT) is 3.6, which means that four children after liver transplantation 
have to be treated with IL-2RA in addition to standard immunosuppressive therapy to prevent one 
patient of having an acute rejection. Four studies defined acute rejection clinically and confirmed it 
by biopsy (1-3, 27). Analysis of this subgroup showed a statistically significant reduction of acute 
rejection (RR 0.40; CI 0.21–0.76; p = 0.0052; 4 trials). One trial (9) used the term of an episode of  
acute rejection as outcome measurement and another study (10) did not state a definition. None of 
the trials were taking protocol biopsies.
Steroid-resistant  rejection. All  trials  reported  data  on  steroid-resistant  rejection.  One  study (9) 
reported about no steroid-resistant rejection in both arms, so that we excluded it from analysis. IL-
2RA in addition to standard double or triple immunsuppressive therapy after liver transplantation in 
children did not reduce steroid-resistant rejection statistically significantly (RR 0.44; CI 0.19–1.03; 
p = 0.0594; 5 trials). If we exclude one of the older studies (1) with the most extreme effect from 
the  analysis,  we  get  a  statistically  significant  reduction  of  steroid-resistant  rejection  without 
significant  heterogeneity  (RR  0.34;  CI  0.14–0.79;  p  =  0.0123;  4  trials).  Stratifying  trials  by 
randomization status (randomized subgroup: RR 0.18; CI 0.04–0.74; p = 0.0177; 2 studies (2-3) and 
nonrandomized subgroup: RR 0.65; CI 0.24–1.78; p = 0.3971; 4 trials (1, 9-10, 27)) and comparison 
did not show statistically significant effects (IL-2RA only comparison: RR 0.77; CI 0.30–1.98; p = 
0.5894; 3 trials (1-2, 27);  delayed CNI comparison (3) and low/no steroids comparison (10) only 
one  study  each)  except  the  subgroup  of  randomized  studies.  However,  we  saw  a  statistically 
significant  reduction  of  steroid-resistant  rejection  in  studies  (3,  10,  27)  with  follow-up 
measurements at 12 months and later (RR 0.33; CI 0.12–0.89; p = 0.0281; 3 trials; Fig.3), but not 
for  6  months  (RR  0.93;  CI  0.18  –4.67;  p  =  0.9269;  2  trials  (1-2)).  There  was  a  statistically 
significant reduction in steroid-resistant rejection by using IL-2RA in subgroups using tacrolimus 
(RR 0.17; CI 0.05–0.57; p = 0.0041; 3 trials (2-3, 10)) and daclizumab induction therapy combined 
with additional MMF dose and prospective control group (RR 0.18; CI 0.04–0.74; p = 0.0177; 2 
trials (2-3)).
Graft loss and patient death. Four studies (3, 9-10, 27) reported data on graft loss and patient death. 
Neither graft loss (RR 0.65; CI 0.34–1.21; p = 0.1737; 4 trials) nor patient death (RR 0.61; CI 0.27–
1.37; p = 0.2296; 4 trials) were statistically significantly reduced by using additional IL-2RA in 
combination to standard immunosuppressive medication in the observation period. In the forest plot 
one study (9) is prominently deviating from the remaining studies. After excluding this study from 
the analysis we saw a statistically significant result for reducing graft loss by the use of IL-2RA (RR 
0.44; CI 0.21–0.92; p = 0.0298; 3 trials), but not for death (RR 0.42; CI 0.16–1.12; p = 0.0831; 3 
trials). However, all analyses show a trend towards a lower incidence of graft loss and patient death 
in the experimental group using IL-2RA in addition to standard double-drug or triple-drug therapy.
Secondary outcomes: Side effects and subgroups
It  was  not  possible  to  collect  enough  data  to  analyse  secondary  outcomes,  namely  de  novo 
malignancy, PTDM or HLP. Four studies reported on renal dysfunction (1, 2, 9, 27); data analysis of 
this outcome showed a slight reductive tendency but no statistically significant reduction by using 
IL-2RA (RR 0.96; CI 0.60–1.54; p = 0.8683; 4 trials). Furthermore three studies (1, 9, 27) reported 
on new onset arterial hypertension (HTN). Analysis showed no significant reduction of HTN by 
using IL-2RA but a reductive tendency (RR 0.85; CI 0.60–1.21; p = 0.3731; 3 trials). Three studies 
(2, 9, 27) reported on PTLD but one of them (2) yielded no event in both arms, so that we excluded 
it from analysis. PTLD was not reduced by using additional IL-2RA therapy (RR 1.6; CI 0.20–
12.67; p = 0.6587; 2 trials), on the contrary, it showed a higher RR in the experimental group. Two 
studies (9, 27) reported on infection complications and outcomes were also reported on subgroups 
named  viral,  bacterial  and  fungal  infections.  Additional  IL-2RA  therapy  with  standard 
immunosuppressive  medication  did  not  reduce  infection  complications  statistically  significantly 
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(infection complications: RR 0.80; CI 0.60–1.07; p = 0.1363; 2 trials; viral infection: RR 1.06; CI 
0.62–1.80;  p  = 0.8356;  2  trials;  fungal  infection:  RR 1.15;  CI 0.46–2.87;  p  = 0.7624;  2  trials;  
bacterial  infection:  RR 0.68;  CI  0.34–1.37;  p  =  0.2838;  2  trials).  Infection  complications  and 
bacterial infection showed a reductive tendency but viral and fungal infection were more frequent in 
the control group. Due to limited data we were unable to do subgroup analyses except for the IL-
2RA only comparison. The subgroup analysis of AE of the  IL-2RA only comparison showed no 
statistically  significant  reduction  by  using  IL2-RA  in  any  of  the  secondary  outcomes  renal 
dysfunction, HTN or PTLD. 
Discussion
The use of IL-2RA in addition to standard double-drug or triple-drug therapy  significantly lower 
the risk of acute rejection in pediatric patients after liver transplantation. Acute rejection rate is 
reduced by two thirds through the use of IL-2RA (RR 0.38). These results are similar to those we 
found in our meta-analysis in adult liver transplant recipients (17).  The relative risk of all studies 
has a significant heterogeneity which is introduced by the study of Gibelli et al. 2004 (1). Most of 
the subgroup analyses support a statistically significant reduction of acute rejection through the 
additional use of IL-2RA, all subgroup analyses showed a substantial reduction by at least 50%.
The  use  of  IL-2RA in  addition  to  standard  double-drug  or  triple-drug  therapy  also  shows  a 
substantial reduction of steroid-resistant rejection after pediatric liver transplantation (RR 0.44). If 
we  exclude  one  of  the  older  and  prominently  deviating studies  (1) from  analysis, we  get  a 
statistically  significant  reduction  of  steroid-resistant  rejection  without  significant  heterogeneity. 
Subgroup analysis stratified by measurement time at 12 months and later, randomized subgroup, as 
well as a subgroup of only prospective controlled trials observed significant reduction of steroid-
resistant rejection through the use of IL-2RA.
Although the risk of acute rejection is substantially reduced when IL2-RA is applied, we did not 
observe a statistically significant reduction in graft loss or patient death. Observed trends suggested 
that the number of patients may be too small to observe significant effects, but we see a clinically  
relevant reduction of patient death (RR 0.61) and graft loss (RR 0.65) by about one third. These 
results are similar to those we found in adult liver transplantated patients (17). 
We also looked at the possibility of reducing concomitant immunosuppressive medication when 
using IL-2RA because most published studies explored this  effect.  We could classify published 
studies  into  three  different  experimental  immunosuppressive  regimes,  namely  the  IL-2RA only 
comparison (1-2, 27), the delayed CNI comparison (3), and the no/low steroids comparison (9-10). 
Stratifying trials by comparison, there is only the IL-2RA only comparison and the no/low steroids 
comparison to analyse. The no/low steroids comparison shows a statistically significant reduction of 
acute rejection favoring the use of IL-2RA. In the analysis of other primary outcomes the number of 
studies in each comparison is too small, so that we find no statistically significant effect in any. We 
see a clinically relevant reductive effect in the IL-2RA only and no/low steroids comparisons of the 
risk of steroid-resistant rejection, patient death and graft loss through the additional use of IL-2RA 
in the experimental group. 
Compared  to  other  types  of  pediatric  solid  organ  transplantations,  we  see  a similar  reductive 
tendency of AR and SRAR in pediatric renal recipients receiving induction therapy with IL-2RA. 
Swiatecka-Urban et al. 2001 (29), a study with retrospective control group, compared basiliximab 
induction and tacrolimus with no treatment in pediatric renal recipients. The use of basiliximab 
induction in addition to tacrolimus and steroids reduce the risk of rate of AR (basiliximab group 
(BG): 26% vs. non-BG: 43%; p = 0.36) and rate of SRAR (BG: 8.7% vs. non-BG: 12.5%; p = 
0.68). No patient deaths were observed within one year follow-up time. The one-year graft survival 
rate was higher in the induction group (BG: 87.5% vs. 75% in non-BG; p = 0.45). These results are  
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comparable with results of other studies, for example Vester et al. 2001 (30). In this prospective 
study using basiliximab as induction combined with cyclosporin A and prednisone one year patient 
survival rate was 100%, graft survival rate was 95%, AR episodes were observed in six patients and 
two  SRAR  were  observed.  Also  a  historical  controlled  study  comparing  basiliximab  with  no 
medication and triple  baseline immunosuppression with cyclosporine or  tacrolimus,  prednisone, 
MMF showed a reduction of AR to 10% in the induction group compared to 38% in the control  
group (31).  There  are  very  few studies  using  IL-2RA in  pediatric  patients  after  lung  or  heart 
transplantation. We found occasional controlled studies while most publications were reviews. One 
controlled study reported about a six-months AR incidence of 30% in the daclizumab group vs. 60% 
in the control group (32). IL-2RA are also used in pediatric patients after heart transplantation (33-
34).  It  seems  to  reduce  acute  rejection  if  basiliximab  is  given  before  transplantation  (35)  and 
reduced AR in critically ill children with heart transplantation (36). IL-2RA induction therapy after 
lung and heart transplantation showed a reductive tendency of AR along with an acceptable safety 
profile,  but  the  reductive  tendency  in  pediatric  patients  seems  to  be  stronger  after  liver 
transplantation compared to published data on renal, heart or lung transplant recipients.
The following side effects were observed after basiliximab application in about 20% of pediatric 
patients by the EPAR: urinary tract infections, hypertrichosis, rhinitis, fever, hypertension, upper 
respiratory tract infection, viral infection, sepsis and constipation (37, p. 2). The EPAR reported 
about  side  effects  of  daclizumab  such  as  insomnia,  tremor,  headache,  hypertension,  dyspnoea, 
constipation,  diarrhoea,  vomiting,  nausea,  dyspepsia,  musculoskeletal  pain,  oedema,  impaired 
healing and post-traumatic pain being observed in more than one out of ten patients (38, p. 2). Of 
these named potential side effects, the analysed studies reported mostly about metabolic disorders, 
for example HTN, and observed infection complications which were not reported in detail. Major 
side effects as lymphoma were observed rarely.
Due to the limited amount of data we were unable to perform subgroup analyses except for the IL-
2RA  only comparison.  Also  it  was  not  possible  to  collect  enough  data  to  analyse  secondary 
outcomes,  namely  de  novo malignancy, PTDM or  HLP. Analysis  of  included  studies  shows  a 
reductive  tendency  of  renal  dysfunction,  new  onset  posttransplant  arterial  hypertension  and 
infection complication especially bacterial infections in experiemtal group which uses IL-2RA in 
addition  to  standard  immunsuppressive  therapy.  The  subgroup  analysis  of  the  IL-2RA  only 
comparison showed no statistically significant reduction by using IL2-RA in any of the secondary 
outcomes called renal dysfunction, HTN or PTLD.
In the published European Public  Assessment  Report  (EPAR) about  simulect  (basiliximab),  the 
weight limit for a higher dose is 35 kg (37). Basiliximab was studied in pediatric and adult kidney 
transplanted patients.  It  was given on postoperative day-0 and 4 (37).  According to the EPAR, 
daclizumab should be given in 1mg/kg on postoperative day 0, 14, 28, 42, and 56 after kidney 
transplantation (38). By comparing the mode of application between analysed studies and EPAR 
statement we see that the authors have used the common dose of basiliximab. Only Spada et al. 
2006 (9) added a third dose, which might hold the level of IL-2RA intracorporeal. The limit of 
weight for a higher dose was lower than proposed by EPAR. Daclizumab was given only once or 
twice  after  liver  transplantation.  Giving a  drug in  one  or  two single  doses  is  a  good practical 
application, promotes the compliance and may shorten the day of hospitalization. 
Strengths and limitations
The  main  limitation  of  this  review is  the  small  number  of  randomized  controlled  trials,  even 
compared to trials in kidney transplantation (39), and our systematic review and meta-analysis of 
adult patients after liver transplantation (17). The low number of studies makes it difficult to acquire 
enough data to demonstrate statistical significance. Corresponding to our experience with studies of 
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adult  liver transplant  recipients (17) we decided to include not  only randomized trials  but  also 
nonrandomized controlled trials and studies with prospective experimental group and retrospective 
control group in this review. Half of them compared IL-2RA to no add-on. The other half explored 
the  effects  of  reduced  or  delayed  concomitant  immunosuppression.  Therefore,  we  decided  to 
include those studies in order to increase the total number of included trials. We also allocated them 
to predefined comparisons of concomitant medication. Furthermore, we included and pooled studies 
that used a different type of IL-2RA, had different concomitant medication (type of CNI and MMF), 
or had different follow-up times. Because all these differences may be sources of heterogeneity, it 
was planned to explore differences of effect by performing subgroup analyses. Because of the small 
number of included studies some studies dominate the results as we have seen in analyses including 
Gibelli et al. 2004 (1) or Spada et al. 2006 (9). Both studies met the inclusion criteria. Due to the 
paucity  of  data  on  secondary  outcomes  we were  only  able  to  extensively  analyze  the  primary 
endpoints. Another problem was the insufficient detailed reporting of outcomes; this was noticed 
most evidently regarding the adverse drug reaction of immunosuppression. Few studies give data on 
complications and ADR, but also these were measured or grouped differently in the various trials. 
We endeavored to overcome this limitation by grouping data on side effects into broader categories, 
but  this  may further  limit  the interpretation of  the results.  Although we attempted to  minimize 
publication bias by searching for and including data from different databases. Nonetheless,  this 
systematic review and meta-analysis gives us a first impression of the evidence and the order of  
magnitude of the effect of using IL-2RA as an induction therapy in addition to standard double-drug 
or triple-drug therapy in pediatric liver transplant recipients. For further analysis we require more 
studies,  but  we  do  not  expect  more  data  to  accumulate  over  the  next  years.  In  order  to  gain 
information on long-term effects of reduced or delayed concomitant immunosuppression, which is 
urgently  needed  in  pediatric  liver  transplant  recipients,  more  prospective  controlled  trials  are 
needed.
Clinical implications
Four  pediatric  patients  would  need  to  be  treated  with  IL-2RA to  prevent  one  acute  rejection 
(NNT ≈ 4). The risk reduction for acute rejection is higher than would be expected from experience 
with  adult  liver  transplantation  (17)  which  could  be  a  result  of  differences  in  the  pediatric 
metabolism.  We have  no  evidence  for  a  difference  in  effectiveness  between  basiliximab  and 
daclizumab in reducing the risk of rejection. In conclusion, the use of IL-2RA reduces the risk of 
acute rejection without a significant increase of harmful effects. This effect may allow for reduction 
of coimmunosuppression to avoid the adverse drug reaction of CNI or steroids. Also we observe a 
substantial reduction of the risk of steroid-resistant rejection, patient death and graft loss by using 
IL-2RA in addition to standard double-drug or triple-drug therapy, and therefore we should value 
this result as clinical relevant.
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Table 1. Characteristics of included trials stratified by the three pre-specified comparison groups
Trial Patient Sample Size Age^ Sex (male) Typ of Control CNI MMF Follow
(Author& 
Year)
Subgroup² Exp Cont Exp Cont Exp Cont IL-2RA Substance -up§
IL-2RA only comparison: IL-2RA vs placebo/no treatment
Ganschow 2005 54 54 4.2 (0.3-8.9)“ matched ns ns Bas no Cya no 36
Gibelli 2004 28 28 3 (1.3-16)“ matched ns ns Bas no Cya no 6
Schuller 2005 18 12 3.95  ± 0.33 3.9  ± 0.26 9 4 Dac no Tac yes 6
delayed CNI comparison: IL-2RA and delayed and/or reduced CNI vs placebo/no treatment and standard immunosuppressive co-
medication
Heffron 2003 61 20 6.8  ± 6.3 5.3  ± 6.6 24 7 Dac ns Tac yes 24
no/low steroids comparison: IL-2RA and minimized steroids or no steroids vs placebo/no treatment and standard immunosuppressive co-
medication
Spada 2006 renal function 36 36 2.9 (1.5-4.3)“ 2.8 (1.5-4.3) 18 15 Bas no Tac no 12
Gras 2008
no auto-
immun
hepatitis
50 34 1.7 (0.4-14.0)“ 2.0 (0.4-14.0) 27 16 Bas no Tac no 36
Abbreviations: Exp – experimental group; Cont – control group; IL-2RA– interleukin-2 receptor antagonist; CNI – calcineurin inhibitor; MMF – 
mycophenolat mofetil; Bas – basiliximab; Dac – daclizumab; Cya – cyclosporine A; Tac – tacrolimus; ns – not stated; vs – versus.
^ - Age is given in mean  ± standard deviation if available. “ - Age is given in mean with (minimum – maximum).
§ - Length of follow-up, time is given in months. ²- Patient Subgroup: Special inclusion criteria used by the authors.
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Table 2. Summary of quality assessment of included trials
Trial Blinding Randomized Control Allocation ITT Missing Completeness of follow-up §
(Author
& Year)
Group Concealment Analysis Values Exp (%) Cont (%) Month
IL-2RA only comparison: IL-2RA vs placebo/no treatment
Ganschow 2005 no no historical na yes^ (ns) ns ns ns 28-52
Gibelli 2004 no no historical na yes* (PP) ns ns ns 6
Schuller 2005 no no concurrent+ na yes^ (ns) ns ns ns 6
delayed CNI comparison: IL-2RA and delayed and/or reduced CNI vs placebo/no treatment and standard immunosuppressive co-
medication
Heffron 2003 ns yes concurrent inadequate ns ns ns ns 24
no/low steroids comparison: IL-2RA and minimized steroids or no steroids vs placebo/no treatment and standard immunosuppressive co-
medication
Spada 2006 ns yes concurrent unclear yes ns 90 90 12
Gras 2008 no no historical na yes^ (ns) ns 100 100 36
Abbreviations: ITT – intention-to-treat;, na – not applicable, ns – not stated; PP – per-protocol; Exp – experimental group; Cont – control group; vs 
- versus.
^ - ITT-analysis is assumed, because the author reported about at least one analysis with the total number of included patients. 
* - author reported that ITT analysis was performed, but also stated conditions that must be met for patient to be included in analysis, such as 
“patient received at least one dose of medication“ and/or “at least one follow-up available“. § - as stated by authors or calculated from available 
data. + - prospective study.
12
Table 3. Immunosuppressive therapy of included pediatric trials
Trial IL-2RA CNI Corticosteroids MMF
(Author
& Year)
Type &
Dosage
Type, First Day of Therapy,
Dosage & Target Level (tl)
Dosage† Dosage
Exp Cont Exp Cont
IL-2RA only comparison: IL-2RA vs placebo/no treatment
Ganschow
2005
Basiliximab
POD 0&4 i.v.
10mg (KG < 30kg)
20mg (KG > 30kg)
Cyclosporine A
tl 150 - 200 μg/L
after one year tl 80 - 100 μg/L
Prednisolone 60 mg/m²
after one week 30 mg/m²
thereafter weekly reduction 
about 5 mg/m²
break off after one year
no
Gibelli 
2004
Basiliximab
POD 0&4 i.v.
10mg (KG < 30kg)
20mg (KG > 30kg)
Cyclosporine A
7 – 13mg/kg/d
tl 850 – 1000 mg/dL
Cyclosporine A
5 – 7 mg/kg/d
tl 850 – 1000 mg/dL
steroids no
Schuller 
2005
Daclizumab
POD 0 & 14 i.v.
1mg/kgKG
Tacrolimus
0.2 mg/kg/d
tl 10-12 ng/mL
Start: POD 3
Tacrolimus
0.2 mg/kg/d
tl 6-8ng/mL
Start: POD 3
Methylprednisolone 20mg/kg
Start: POD 0
fast reduction
break off after 4th months
1200mg/m²/d 
Start: POD 14
delayed CNI comparison: IL-2RA and delayed and/or reduced CNI vs placebo/no treatment and standard immunosuppressive co-
medication
Heffron 
2003
Daclizumab
POD 0 i.v.
1mg/kgKG
Tacrolimus 
0.15/mg/kg/d
tl 10-14ng/mL
Start: POD 7
Tacrolimus 
0,15/mg/kg/d
tl 10-14ng/mL
Start: POD 0
Methylprednisolon: 
POD 0: 20mg/kg/d, 
POD 6: 0,3mg/kg/d
30mg/kg/d, p.o.
no/low steroids comparison: IL-2RA and minimized steroids or no steroids vs placebo/no treatment and standard immunosuppressive co-
medication
Spada
2006
Basiliximab
POD 0 & 4 &
POD 8-10 i.v.
10mg (KG < 35kg)
20mg (KG > 35kg)
Tacrolimus
0.04 mg/kg/d, p.o.
tl 1th month 10-15 ng/mL
tl 2th-3th month 10-15ng/mL
tl 4th-6th month 6-8ng/mL
thereafter 5-7ng/mL
Methyl-
prednisolone
i.o. 10mg/kg i.v.
Methylprednisolone
i.o. 10mg/kg i.v.
POD 1-6: 2mg/kg/d
POD 7: 1mg/kg/d
break off after 3th - 6th 
months
maximum: 40mg
no
Gras
2008
Basiliximab
POD 0 & 4 i.v.
10mg (KG < 35kg)
20mg (KG > 35kg)
Tacrolimus
0.2 mg/kg/d, p.o.
Start: POD 0
tl 1th month 8-12 ng/mL
thereafter 5-8 ng/mL
no
Methylprednisolone 
10mg/kg/i.v.
POD1 - 6: 2 mg /kg/d i.v.
POD7 – 13: 1mg/kg/d p.o.
POD14-20: 0.75 mg/kg/d
POD 21-28: 0.5 mg/kg/d
thereafter 0.25 mg/kg/d
POD 90: 0.25mg/kg/d
(cave: alternative therapy 
in 2th -6th months)
20 mg/kgKG/d
(only the first 9 
children took it)
Abbreviations:  i.o. – intraoperative; POD – postoperative day; Tac – tacrolimus; tl – target level; KG - body weight; kgKG – kilogamme body 
weight; Exp – experimental group; Cont – control group; na - not applicable (drugs were not used), ns – not stated (drugs were used but not 
specified), vs – versus. 
† - All trials used methylprednisolone intraoperatively. In the postoperative period they used methylprednisolone or prednisolone.
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Fig. 1. Flow chart of systematic review. IL-2 RA - interleukin-2 receptor antagonist (according to 
PRISMA (16)) Abbreviations: CNI - calcineurin inhibitor; OLT - orthotopic liver transplantation
(150.8mm x 165.9mm)
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Fig. 2. Forest plot of acute rejection of all included studies. The forest plot shows a reduced relative 
risk of acute rejection for pediatric patients which have used IL-2RA (experimental group). The 
result is significant,  but also shows significant heterogeneity (p = 0.0126). Abbreviations: RR - 
relative risk; 95%-CI - 95% confidence interval; p – p value for test of heterogeneity; Experimental  
- experimental group, Control - control group.
(210mm x 73.8mm)
Fig. 3. Forest plot of steroid-resistant rejection stratified by follow-up measurement, here follow-up 
12 months and later. The forest plot shows a reduced relative risk of steroid-resistant rejection for 
pediatric  patients  which  have  used  IL-2RA (experimental  group).  The  result  is  significant  and 
shows no significant heterogeneity (p = 0.3058). Abbreviations: RR - relative risk; 95%-CI - 95% 
confidence  interval;  p  –  p  value  for  test  of  heterogeneity;  Experimental  -  experimental  group, 
Control - control group.
(210mm x 65.8mm)
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